Primary reasons for study exclusion during prescreening included life expectancy ≤2 years and patients diagnosed with leukemia or pancreatic cancer (16.9%), current use or inability to tolerate metformin (14.8%), and abnormal labs that contraindicated metformin use (eGFR, AST/ALT) (13.9%). The gene discussed is GPT; the disease is leukemia.